Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $1.00 $1.00 Thursday, 9th May 2024 ONTX stock ended at $1.00. During the day the stock fluctuated 0% from a day low at $1.00 to a day high of $1.00.
90 days $0.650 $1.10
52 weeks $0.551 $1.33

Historical Onconova Therapeutics prices

Date Open High Low Close Volume
May 09, 2024 $1.00 $1.00 $1.00 $1.00 0
May 08, 2024 $1.00 $1.00 $1.00 $1.00 0
May 07, 2024 $1.00 $1.00 $1.00 $1.00 0
May 06, 2024 $1.00 $1.00 $1.00 $1.00 0
May 03, 2024 $1.00 $1.00 $1.00 $1.00 0
May 02, 2024 $1.00 $1.00 $1.00 $1.00 0
May 01, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 30, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 29, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 26, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 25, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 24, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 23, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 22, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 19, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 18, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 17, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 16, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 15, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 12, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 11, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 10, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 09, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 08, 2024 $1.00 $1.00 $1.00 $1.00 0
Apr 05, 2024 $1.00 $1.00 $1.00 $1.00 0
Click to get the best stock tips daily for free!

About Onconova Therapeutics

Onconova Therapeutics Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with P... ONTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT